Editas Medicine (EDIT) Revenue & Revenue Breakdown
Editas Medicine Revenue Highlights
00
Editas Medicine Revenue by Period
Editas Medicine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $19.71M | -22.83% |
| 2021-12-31 | $25.54M | -71.85% |
| 2020-12-31 | $90.73M | 341.93% |
| 2019-12-31 | $20.53M | -35.71% |
| 2018-12-31 | $31.94M | 132.64% |
| 2017-12-31 | $13.73M | 126.80% |
| 2016-12-31 | $6.05M | 271.58% |
| 2015-12-31 | $1.63M | 100.00% |
| 2014-12-31 | - | - |
Editas Medicine generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $513.00K | -54.80% |
| 2024-03-31 | $1.14M | -98.11% |
| 2023-12-31 | $60.05M | 1025.36% |
| 2023-09-30 | $5.34M | 84.83% |
| 2023-06-30 | $2.89M | -70.69% |
| 2023-03-31 | $9.85M | 50.72% |
| 2022-12-31 | $6.54M | 15461.90% |
| 2022-09-30 | $42.00K | -99.34% |
| 2022-06-30 | $6.36M | -6.04% |
| 2022-03-31 | $6.77M | -45.70% |
| 2021-12-31 | $12.47M | 101.21% |
| 2021-09-30 | $6.20M | 1535.09% |
| 2021-06-30 | $379.00K | -94.17% |
| 2021-03-31 | $6.50M | -43.09% |
| 2020-12-31 | $11.42M | -81.83% |
| 2020-09-30 | $62.84M | 484.62% |
| 2020-06-30 | $10.75M | 87.82% |
| 2020-03-31 | $5.72M | -53.41% |
| 2019-12-31 | $12.28M | 219.23% |
| 2019-09-30 | $3.85M | 65.15% |
| 2019-06-30 | $2.33M | 12.61% |
| 2019-03-31 | $2.07M | -66.19% |
| 2018-12-31 | $6.12M | -57.86% |
| 2018-09-30 | $14.52M | 96.95% |
| 2018-06-30 | $7.37M | 87.73% |
| 2018-03-31 | $3.93M | 7.09% |
| 2017-12-31 | $3.67M | -41.63% |
| 2017-09-30 | $6.28M | 102.84% |
| 2017-06-30 | $3.10M | 354.11% |
| 2017-03-31 | $682.00K | -24.05% |
| 2016-12-31 | $898.00K | -6.65% |
| 2016-09-30 | $962.00K | -71.61% |
| 2016-06-30 | $3.39M | 320.87% |
| 2016-03-31 | $805.00K | 1.64% |
| 2015-12-31 | $792.00K | 18.21% |
| 2015-09-30 | $670.00K | 301.20% |
| 2015-06-30 | $167.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | - |
Editas Medicine generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.77B |
| BEAM | Beam Therapeutics | $377.71M | $14.27M |
| CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
| DNA | Genie Energy | $251.46M | $89.05M |
| NTLA | Intellia Therapeutics | $36.27M | $9.11M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $6.87M |
| ALLO | Allogene Therapeutics | $95.00K | - |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | $39.31M |
| SANA | Sana Bio | - | - |